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Abstract
Keratoconus is a bilateral, asymmetric, progressive disease of the cornea which 
can lead to visual impairment and blindness as irregular astigmatism increases 
and corneal scar occurs. Currently, many methods are available for a treatment 
of keratoconus. The treatment can help enhance visual rehabilitation and prevent 
progression in keratoconus patients. The treatment options included non-surgical 
and surgical managements. This review offers a summary of the current and emerg-
ing treatment options for keratoconus- eyeglasses, contact lens, corneal collagen 
cross-linking (CXL), CXL Plus, intrastromal corneal ring segment (ICRS), Corneal 
Allogenic Intrastromal Ring Segments (CAIRS), Penetrating Keratoplasty (PK), 
Deep Anterior Lamellar Keratoplasty (DALK), Bowman layer transplantation (BL 
transplantation) and gene therapy.
Keywords: corneal collagen cross-linking, CXL, CXL Plus, intrastromal corneal ring 
segment, ICRS, PK, DALK, Bowman layer transplantation
1. Introduction
Keratoconus is a bilateral, asymmetric, progressive ectatic disease of the cornea 
characterized by progressive corneal thinning which can lead to visual impairment 
and blindness as corneal protrusion progresses, irregular astigmatism increases 
and corneal scar occurs [1]. Keratoconus is often under the radar because of 
decreased awareness, underdiagnosis and undertreatment. The exact pathologi-
cal mechanism remains unknown, but both genetic and environmental factors 
may contribute to development and progression of this disease [2]. The reported 
evidences of pathogenesis of keratoconus include histochemistry, biomechan-
ics, enzymology, proteomics, and molecular genetics [2]. The disease process 
starts with fragmentation of the epithelial basement membrane, fibrillation of 
Bowman’s membrane and anterior stroma [3]. Bowman’s membrane breakage 
occurs later together with epithelial abnormality resulting in proteolytic enzymes 
release that weakens corneal stromal collagen and stromal thinning [3]. The 
reported prevalence of keratoconus varies between countries and ethnicities, in 
which Asian is higher than Caucasian about 4.4 to 7.5 times [4, 5]. The prevalence 
is ranged from 0.3 in 100, 000 to 2300 in 100,000 in Russia and India respectively 
[6]. However, the prevalence may be higher in tertiary eye care center or refractive 
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surgery center [7]. Keratoconus is more common in men than women, although 
both gender are affected [5]. The onset of symptoms usually presents during ado-
lescent and may progress until the 30s. Keratoconus is associated with eye rubbing 
such as in allergic conjunctivitis, floppy eyelid syndrome, obstructive sleep apnea, 
Down’s syndrome and Leber congenital amaurosis [1, 8–10]. Genetic predisposi-
tion accounts for an increased risk of keratoconus in patient that has a positive 
family history about 15 to 67 times [11].
2. Terminology and staging
Nowadays, there remain many controversies regarding disease definition, diag-
nosis, and management of keratoconus. Keratoconus is usually a bilateral disease 
in which the normal contralateral eye is believed to be in the preclinical stage of 
keratoconus with different terms such as subclinical keratoconus, keratoconus sus-
pect, forme fruste keratoconus [12]. Despite the advancement of the investigations 
for the diagnosis of keratoconus and subclinical keratoconus, there are no definitive 
criteria for discriminating subclinical keratoconus from normal cornea currently 
[13]. The detection of keratoconus and subclinical keratoconus is crucial to prevent 
ectasia after refractive surgery. Moreover, some treatment modalities such as cor-
neal collagen crosslinking can prevent vision loss in keratoconus if implement in the 
early stage of the disease [14]. The early stage symptoms may manifest as reduced 
vision, fluctuation of vision, progressive myopia and astigmatism, increasing 
higher order aberrations [4, 15]. When the disease progresses into an advance stage, 
there is a severe visual loss from high myopia, irregular astigmatism and corneal 
scarring.
The following criteria are mandatory to diagnose keratoconus- abnormal 
posterior elevation, abnormal corneal thickness distribution and clinical non-
inflammatory corneal thinning [10]. However, there is no clinically adequate 
classification system for keratoconus currently. One of the most popular grading 
systems is Amsler-Krumeich classification system which classified severity of 
diseases based on the amount of myopia and astigmatism, corneal thickness or 
scarring and central keratometry readings [16, 17]. However, Amsler-Krumeich 
classification system is considered as outdated because it relies on “old” indices 
(corneal steepness, refractive change, the presence of scarring), and fails to 
address disease impact [18]. Nowadays, other alternate classification systems are 
growing in number such as Shabayek-Alio system which is based on corneal higher 
aberrations and the keratoconus severity score (KSS) which considers average 
corneal power and root mean square (RMS) [19, 20]. The “ABCD grading system” 
that incorporates anterior and posterior corneal curvature, thinnest pachymetric 
values based on the thinnest point and distant visual acuity may better reflects the 
anatomical change than some previous classification that uses pachymetric value 
based on apical measurement [21]. In routine clinical practice, the term “advanced 
keratoconus” usually apply to any case with unacceptably poor spectacle distance 
vision and contact lens intolerance [18].
3. Diagnosis
The keratoconus diagnosis is bases on the history and clinical examination. 
However, the investigations are very useful to augment the clinical examination 
and detect the early stage of disease. Moreover, the accurate diagnosis and early 
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detection of keratoconus in essential in this era which laser refractive surgery 
has increased markedly. Failure to detect keratoconus and subclinical keratoco-
nus can lead to ectasia after refractive surgery [22]. Corneal topography is the 
primary diagnostic tool for keratoconus detection. However, corneal topography 
is not a faultless method and therefore other diagnostic tools such as corneal 
pachymetry to characterize the corneal thinning and aberrometry to characterize 
degradation of the corneal optics should be used as complimentary techniques 
[22]. Corneal tomography which based on rotating Scheimpflug camera, such 
as Pentacam, Galilei, or Sirius systems, provide the topographic, pachymetric, 
and aberrometric information simultaneously as their use is adequate enough for 
the keratoconus detection [12, 22]. Currently, OCT technology is being used to 
differentiate between eye with keratoconus and normal eye because it can provide 
accurate pachymetric characterization, define epithelial thickness irregularity 
and asymmetry that present in keratoconus [7, 23]. By analyzing the biomechani-
cal properties of the cornea that may precede the anatomical change, the Ocular 
Response Analyzer and Corvis systems can provide good diagnostic accuracy [22]. 
Analysis of the Corneal Microstructure change in keratoconic eye from confocal 
microscopy such as reducing corneal nerve fiber density and nerve fiber length, 
reducing keratocyte density, increasing corneal stromal nerve thickness, may be 
useful in detecting structural changes occurring before manifestation of topo-
graphic signs [22, 24]. A combination of multiple imaging modalities, including 
corneal topography, corneal tomography, Scheimpflug imaging, anterior segment 
optical coherence tomography, and in vivo confocal microscopy will enhance early 
keratoconus detection. Modalities during investigations but show promise include 
polarization-sensitive optical coherence tomography, Brillouin microscopy, and 
atomic force microscopy [25].
4. Disease progression
Keratoconus progression detection is a critical issue because the treatment 
nomograms have been proposed based on the grading system and ectasia progres-
sion [15, 22]. Moreover, the disease progression is differed considerably among 
individual. The younger the patients are, the higher their risk for rapid progression 
[26]. Currently, there is no global consensus of ectasia progression. The Group 
of Panelists for the Global Delphi Panel of Keratoconus and Ectatic Diseases had 
defined the definition of “ectasia progression” as a consistent change overtime in at 
least 2 of the following parameters where the magnitude of the change is above the 
normal noise of the testing system:
1. Steepening of the anterior corneal surface.
2. Steepening of the posterior corneal surface.
3. Thinning and/or an increase in the rate of corneal thickness change from the 
periphery to the thinnest point” [10].
Various clinical studies have used different parameters to define disease progres-
sion. The most important parameters include: [27, 28]
1. An increase in maximum corneal refractive power (Kmax) by more than 
1  diopter (D) within 1 year
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2. An increase in (corneal) myopia by more than 3 D or astigmatism by more 
than 1.5 D within 12 months
3. An increase in mean corneal refractive power by more than 1.5 D within 
12 months
4. A reduction in minimal corneal thickness of more than 5% within 12 months.
The regular topographic/tomographic check-ups can identify keratoconus 
progression. Regarding the examination intervals, the individual risk profiles need 
to be taken into consideration. The risk factors that should be considered include 
eye rubbing, ocular allergies, young age, steep corneal curvature gradient, high 
astigmatism, marked visual loss, documented progression in the fellow eye, atopic 
dermatitis or Down’s syndrome [28]. In children, keratoconus tends to be more 
severe and progress faster requiring closer follow-up intervals [26]. The patient with 
low risks can be monitored less frequently than the one with high risks. Keratoconus 
progression is often associated with a decrease in best spectacle-corrected visual 
acuity (BSCVA), however, a change in both uncorrected visual acuity and BSCVA is 
not required to document progression [10].
5. Treatment
The important goals of keratoconus management are stopping disease progres-
sion and visual rehabilitation [10]. In cases of ocular allergies, patients should be 
treated with topical antiallergy and lubricants and should be instructed to avoid eye 
rubbing to halt disease progression. Corneal collagen crosslinking is a promising 
procedure to stop disease progression with minimal side effects [29]. For the visual 
rehabilitation, several treatment options corresponding to keratoconus grading 
have been established. Keratoconus can be treated by both nonsurgical and surgical 
approaches depend on severity and progression of the disease [15]. The keratoconus 
treatment toolbox is listed as in Table 1.
Nonsurgical treatments Surgical treatments
• Glasses
• Contact lens (CL)















CXL + ICRS + phakic IOLS
CXL in thin cornea
• Intrastromal corneal ring segments (ICRS)
• Corneal transplantation
Penetrating keratoplasty (PK)
Deep Anterior Lamellar Keratoplasty (DALK)
Bowman layer transplantation
RGP = Rigid gas permeable contact lens, IOL = intraocular lenses, PBCL = Piggyback lens, TG-PRK = Topo guided- 
Photo Refractive Keratectomy.
Table 1. 
The keratoconus treatment toolbox.
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5.1 Nonsurgical treatment
A nonsurgical treatment of keratoconus is spectacles and contact lens. For 
early stage of disease, those who achieve visual acuity 20/40 or better, spectacles 
can provide acceptable vision [15]. A toric soft contact lens also provides satisfac-
tory vision for correcting myopia and regular astigmatism in early keratoconus. 
However, as the diseases progress, spectacles or soft contact lens may not provide 
acceptable vision because of the higher- order aberrations, in particular vertical 
coma was increased [30]. Therefore, other special lens such as rigid gas permeable 
(RGP) contact lens, hybrid lenses, piggy back, miniscleral lens, semiscleral lens or 
scleral lenses are needed to provide satisfactory vision [31]. The ultimate goal of 
fitting contact lens in keratoconus is to improve visual acuity without compromise 
ocular health. However, contact lens use does not slow or stop progression of the 
disease. In keratoconus, the cone is steeper but the cornea beyond the cone is flatter. 
In mild keratoconus, traditional RGP lens can provide an ideal fit. However, as the 
disease progress into advanced stages, it becomes difficult to achieve an ideal fit 
but compromised fit which is not damage to the ocular surface is acceptable. High 
oxygen transmissibility lens should be selected to prevent hypoxic-related corneal 
changes [31].
The type of contact lens selection is based on manifest refraction, degree of 
keratoconus, and morphology of the cone [31]. Corneal topography can aid in 
addressing the severity and morphology of the cone. Buxton et al. have classified 
keratoconus based on keratometry values (K) at the apex of the cone: mild if K is 
less than 45 D, moderate if K is between 45 and 52 D, advanced if K is more than 52 
D and severe if K is more than 62 D [32]. The morphology of the cone is classifed as 
the following [33].
• nipple cone: small, paracentral, steeper located inferiorly or inferonasally
• oval cone: inferiorly or inferotemporally steeper cornea
• globus cone: overall steeper cornea, involves more than three forth of the 
cornea up to limbus
The three essential parameters in contact lens fitting are power, diameter, and 
base curve of contact lens.
• Power: Low minus for mild keratoconus, high minus for severe keratoconus
• Base curve: Flatter base curve for mild keratoconus, steeper base curve for 
severe keratoconus
• Diameter: Based on the cone location, its size and steepness, nipple has a small 
diameter, usually start with a small diameter such as 8.7 mm, oval cone needs 
larger diameter lens, globus cone or severe apical displacement need large 
diameter contact lens.
A contact lens type is selected based on the manifest refraction and the degree 
of keratoconus. The contact lens of choice for keratoconus patients is RGP lens. 
However, if the patients develop intolerance or discomfort, customized soft toric 
contact lens, PBCL, hybrid lens or scleral lens can be considered. The indications, 
advantages and disadvantages of each contact lens type are summarized as in 
Table 2 [30, 31, 34]. Fitting contact lens in keratoconus can improve vision and 







• For mild KC




• Prior to PBCL
• Comfort • Cannot correct irregular 
astigmatism
RGP • First lens of choice 
for KC patient
• First lens of 
choice for visual 
improvement
• Can correct 
irregular 
astigmatism
• Less comfortable than 
other CLs
• Need lens adaptation
• Inappropriate fitting 
can compromise ocular 
health






• Inability to obtain 
optimal RGP fitting
• Poor RGP centering
• Reduced wearing 
time with RGP






• Discomfort or RGP 
intolerance
• Irregular cornea 
where RGP lens fit-
ting are not possible
• (unstable RGP on 
the eye, popping out 
of lens
• 3 and 9 o’ clock 
staining with RGP
• Corneal scarring
Comfort • Lost RGP
• GPC








• All options fail to 
improve vision
• Inability to get an 
optimum fit with 
RGP
• RGP intolerance
• 3 and 9 o’ clock 
staining with RGP









• Delays or obvi-
ates the need for 
keratoplasty
• Difficult in care regimen 
(require different 
removal and insertion 
technique)
• Contraindicate in corneal 
edema, acute hydrops, 
post filtration surgery
RGP = Rigid gas permeable, Hybrid lens = rigid lens in the center and a soft skirt in the periphery, PBCL = Piggy 
back lens (RGP lens sitting on top of a soft contact lens) KC = keratoconus, GPC = giant papillary conjunctivitis, 
VA = visual acuity.
Table 2. 
Contact lens in keratoconus (KC).
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delay the need for keratoplasty. Moreover, contact lens in keratoconus patient 
also have a role in correcting residual refractive error after Corneal collagen 
cross-linking (CXL), after Intrastromal corneal ring segments (ICRS) or post-
keratoplasty [31].
5.2 Surgical treatment
Even though the specialized imaging device can provide grading scheme of kera-
toconus, for practical purposes, the term “advanced keratoconus” may apply to any 
cases that have unacceptably poor spectacle distance vision and contact lens intoler-
ance. As the diseases progress, spectacles or contact lens cannot provide acceptable 
vision. This group of patients requires a surgical management such as Corneal col-
lagen cross-linking (CXL), Intrastromal corneal ring segments (ICRS), and Corneal 
transplantation to restore vision and/or stabilize progression of diseases.
The special considerations in surgical management of keratoconus are listed in 
Table 3.
5.2.1 Corneal collagen cross-linking (CXL)
Keratoconus typically progresses until the fourth decade, when most but not 
all, slows or stabilizes [36]. Corneal crosslinking (CXL) has been proposed as a 
new treatment modality to stop progression of keratoconus since the late 1990s 
[27]. Currently, CXL is the gold standard and only minimally invasive surgical 
procedure that halt the progression of keratoconus [27]. The indications for 
CXL are progressive keratoconus in adults and postoperative ectasia, central 
corneal thickness more than 400 μm, Kmax 58 D or less [36, 38]. However, the 
procedure is not approved for stable keratoconus currently. CXL is the promising 
treatment that can prevent progressive visual loss due to disease evolution and 
delay invasive surgical procedures such as corneal transplantation. The mecha-
nism of cornea strengthening is a photochemical reaction of corneal collagen 
by the Riboflavin as a photosensitizer in the photopolymerization process and 
ultraviolet A irradiation (UVA). The interaction between Riboflavin and UVA 
can increases the formation of intrafibrillar and interfibrillar carbonyl-based 
 collagen covalent bonds [37].
The standard Dresden protocol was proposed as a treatment option for kera-
toconus by Wollensak et al. in 2003 [38]. This standard technique is conducted 
under topical anesthesia. The central corneal epithelium is removed followed by 
application of 0.1% riboflavin solution (0.1% riboflavin in 2o% dextran solution) 
as a photosensitizer every 5 minutes for 30 minutes. Then the cornea is exposed 
to 370 nm UVA with an irradiance of 3 mW/cm2 or 5.4 J/cm2, during which time 
riboflavin solution is re-applied every 5 minutes. After the treatment, topical 
antibiotics eye drops are applied and bandage contact lens placed upon the eye [38]. 
Although this standard protocol has been proven to be an effective procedure to halt 
keratoconus progression [39], it is a time-consuming procedure, may create patient 
discomfort and has post-operative complications related to corneal abrasion. The 
reported complications in association with CXL include corneal haze, corneal 
infection, corneal edema, and corneal melting. Adverse effects are common but 
mostly transient and of low clinical significance [40]. However, anterior corneal 
stromal haze is a typical postoperative finding that often occurs in the first month 
after treatment and typically resolves after 12 to 20 weeks [41]. The posterior aspect 
of this haze is an indistinct hyperreflective demarcation line seen in the mid stroma 
that represents the depth of CXL [37]. Two trends have emerged to modify the 
standard Dresden protocol. The first is a tendency to shorten treatment times [42]. 
Alternative treatment protocols with different formulations of riboflavin solution 






CCT > 400 μm can use standard Dresden protocol
CCT < 400 μm
• Hypotonic riboflavin solution                           
Epi-on CXL*
• Pachymetry-guided epithelial debridement  
Decreasing the UVA irradiance dose
• Reducing the duration of riboflavin soaking   
Increasing the riboflavin concentration
or a combination of the above
• ICRS: minimum corneal thickness at the site of their insertion and along 
the length of their path >400 μm
• Bowman layer transplantation: do not affect
• DALK: Prefer Melles manual dissection than Anwar “big-bubble” 
technique
• PK: not suitable for significant peripheral thinning
DALK or modified procedure “tuck-in lamellar keratoplasty” may be 
preferable
Kmax • CXL: risk of failure, continue progression in Kmax > 58 D, increase risk of 
losing vision in Kmax > 55 D
• ICRS: associated with poorer visual outcomes and more complications 
in Kmax > 58 D
• Bowman layer transplantation: do not affect
• DALK: central curvatures >60 diopters (D) may experience worse 
outcomes
• PK: do not affect
Preoperative BCVA • CXL, ICRS, Bowman layer transplantation: rarely do the visual gain 
exceed 1 0r 2 lines
• DALK or PK: extremely poor vision
Endothelial health • CXL: risks of endothelial damage if CCT < 400 μm
• ICRS, Bowman layer transplantation, DALK: No or mild endothelial 
dystrophy
• PK: advanced KC and a failed endothelium
Lens status • CXL, ICRS, Bowman layer transplantation: not promote cataractogen-
esis, preferable options for phakic eyes
• DALK: No/less cataractogenesis than PK
• PK: cataractogenesis, may be the least desirable option for phakic eyes
Patient age (Pediatric) • CXL: modest corneal flattening effect, mild visual benefit without any 
additional complications, smaller gain and less durable than adults
• ICRS: approved for age > 18 years (worldwide), 21 years in US, no 
difference between visual outcome or corneal topography between 
different age groups
• Bowman layer transplantation: extraocular procedure, one of the 
safest options
• DALK: similar outcomes with adults
• PK: outcomes are slightly worse, principally attributable to higher rates 
of graft rejection, failure
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and delivery methods by altered UV exposures have been proposed. These newer 
techniques can shorten duration times, reduce patient discomfort, and minimize 
postoperative complications. The second trend is “epi-on” approach, such that the 
epithelium remains intact during CXL. These modifications were described in the 
following sections.
5.2.1.1 Accelerated CXL (ACXL)
According to Bunsen- Roscoe law of photochemical reciprocity, which states that 
“the same photochemical effect can be achieved with a reduced irradiation interval 
provided the total energy level is kept constant through a corresponding increase 
in irradiation intensity” [37]. ACXL is a modified CXL technique that increase the 
intensity of ultraviolet A (UV-A) irradiation and shortening the exposure time 
without altering the total energy delivered. Currently commercial devices now offer 
ultrafast settings such as 43 mW/cm2 for 2 minutes [42]. Using this setting, would 
achieve the standard Dresden protocol energy dose of 3.4 J or a radiant exposure of 
5.4 J/cm2 within 2 minutes [42]. However, it ignores the requirement of oxygen in 
the CXL reaction, the time needed for oxygen replenishment, and potential physi-
cal damage due to higher irradiance [36]. The reduced efficacy of ACXL is believed 
to be due to depletion of oxygen in these high-fluence treatments [43]. The efficacy, 
safety, and treatment protocols of accelerated CXL are still being investigated and 
in evolution.
Considerations Details
Ability to cooperate 
(Mental disability)
• CXL: risk of postoperative complications, only patients capable of 
reliable cooperation, with good family support
• ICRS: less risky and fewer postoperative requirements than CXL, DALK, 
PK but aware of ICRS stem from migration/ superficialization from eye 
rubbing
• Bowman layer transplantation: less risky and fewer postoperative 
requirements than CXL, DALK, PK
• DALK: may be preferred over PK





• CXL: may be less successful, cannot replace corneal scar then central 
corneal scar is a relative contraindication
• ICRS, Bowman layer transplantation: central corneal scar is a 
contraindication, may arrest disease progression and permit continued 
CL wear in non- visually disabling scarring
• DALK: may be preferred over PK, prefer Melles manual dissection, 
Anwar “big-bubble” technique is contraindicated
• PK: outcomes tend to be worse (not be considered mandatory to replace 
endothelium)
CCT = central corneal thicknesses, Epi-on CXL = Epithelium-0n Corneal collagen cross-linking, 
ICRS = Intrastromal corneal ring segments, DALK = Deep Anterior Lamellar Keratoplasty, PK = Penetrating 
keratoplasty, D = diopter, KC = keratoconus, Kmax = Maximal corneal steepness, BCVA = best corrected visual acuity.
Adapted from Surv Ophthalmol. 2015 Sep;60(5):459–80. [18] J Cataract Refract Surg. 2015 Apr;41(4):842–72 
[37].*currently little to recommend UV-CXL in corneas thinner than 400 μm [18] .
Table 3. 
Special considerations in surgical management of keratoconus.
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5.2.1.2 Epi-on CXL/transepithelial CXL
Due to the epithelial debridement is a major contributor to the postoperative 
complications of CXL, such as infective keratitis and an abnormal wound-healing 
response [37]. This issue has perpetuated interest in epithelium-on technique. 
Epi-on CXL has less discomfort to the patient and reduces postoperative com-
plications [43]. This CXL technique has low complication rate, 0% to 3.9% of 
the patients has only transient haze [37]. According to the hydrophilic property 
of riboflavin solution, the penetration through the intact hydrophobic corneal 
epithelium is difficult. The standard formulations show minimal penetration 
through intact epithelium. The modifications by adding various additives, such as 
benzalkonium chloride, topical anesthetic, tris(hydroxymethyl) aminomethane 
(trometamol), sodium ethylenediaminetetraacetic acid, have been proposed 
to improve epithelial permeability to riboflavin [36]. Riboflavin penetration 
can be improved by increased riboflavin concentration and iontophoresis [36]. 
Since even the low amount of riboflavin surface films will markedly block UV-A 
transmission, transepithelial formulations are often rinsed from epithelial surface 
before irradiation [36]. The iontophoretic delivery system uses of mild electrical 
current for delivering riboflavin through the epithelium [36]. It allows greater 
and deeper riboflavin penetration in the corneal stroma than the conventional 
epithelium-on technique. Overall, the effectiveness of transepithelial techniques 
has been disappointing [27]. Epi-on CXL has limited keratocyte apoptosis, 
shallower demarcation line and less biomechanical rigidity than standard epi-off 
CXL [37]. In general, better outcomes can be achieved by standard epithelium 
off technique and epi-on CXL have resulted in progression of the disease after 
treatment [36, 44]. However, recent research with innovative transepithelial CXL 
system achieved 4-fold higher corneal stromal concentrations of riboflavin than 
commercially available epi-on CXL system, and this level is theoretically adequate 
for effective CXL [44].
5.2.1.3 Pulsed-light accelerated CXL (PLA-CXL)
Due to the presence of oxygen is required for CXL, but high-exposure doses of 
UVA light cause a decrease in the oxygen concentration rapidly [45]. The recent 
technique has focused on pulsing the UVA light with “on” and “off” periods to 
increase the efficacy of CXL treatment by replenishing the consumed oxygen [46]. 
This technique is an effective treatment modality to stop progression in progressive 
keratoconus but regresses some of the cases [46].
5.2.1.4 CXL plus
Despite the fact that CXL can halt the progression of keratoconus and provide 
corneal stability, functional visual acuity remains a problem [47]. Recent data from 
the systematic review disclosed that conventional epi-off CXL can flattening cornea 
2 D approximately and improving visual acuity 2 lines or 10 letters on average [48]. 
CXL normalizes the corneal shape by changing the physical properties of the cor-
nea, resulting in reduction of all corneal aberrations, high order and low order. The 
improvement in uncorrected distance visual acuity (UDVA) and corrected distance 
visual acuity (CDVA) are related to improvement in the total corneal aberrations 
and only high-order aberrations respectively [49].
In order to address this issue, CXL can be performed alone or in combination 
with topo guided photorefractive keratectomy (PRK), ICRS, phakic IOLS or Topo 
guided PRK plus ICRS for better improvement of visual acuity [15].
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• CXL + Topo guided PRK
Kanellopoulos et al. reported the first case of topography-guided PRK per-
formed 1 year after CXL for treatment of keratoconus and showed visual acuity 
improvement [50]. On the contrary, the Athens protocol which combines accel-
erated UV-CXL with same-day photorefractive keratectomy (PRK) was more 
effective with improvement in UDVA and CDVA of 20/45 or better (2.25 logMAR) 
was founded in 83% of patients at last follow up [51]. However, this study was 
conducted in post-LASIK ectasia [51]. Same-day simultaneous topography guided 
PRK CXL in progressive keratoconus appears to be superior to sequential CXL 
with later PRK (6 months later) in the aspect of UCVA, BSCVA, spherical equiva-
lent (SE) and mean reduction in K [52]. This combined technique also prevents 
regression of keratoconus and reduce the risk of keratectasia and might be suit-
able for eyes requiring improvements in irregular astigmatisms but still have good 
CDVA [47, 53].
• CXL + ICRS
The CXL can be performed before, simultaneously or after the ICRS. The advan-
tage of performing the CXL first is slowing the progression of the keratoconus and 
selects the best alternative way to treat the residual refractive error [54]. The recent 
systematic review and meta-analysis demonstrated that simultaneous ICRS implan-
tation and CXL may provide better outcomes in term of refraction and keratometry. 
However, UDVA, BCVA and cylindrical refractive error were similar between 
combined technique and staged procedure [55]. The combined procedure of CXL 
plus ICRS implantation appears safe and efficacious for the treatment of progressive 
keratoconus with significant improvements in visual acuity, keratometry values, 
and refractive error [54]. This technique might be effective for eyes with more 
irregular astigmatism and worse CDVA [53].
• CXL + Topo guided PRK + phakic IOLS
The simultaneous topography-guided photorefractive keratectomy (PRK) and 
crosslinking (Athens protocol) followed by phakic intraocular lens (IOL) implanta-
tion 2–4 months later for managing keratoconus improved and stabilized visual 
performance in patients with keratoconus. The Kmean, SE, UDVA, CDVA improved 
significantly. At last follow-up, all eyes could achieve CDVA of 0.3 or better [56].
• CXL + ICRS+ + phakic IOLS
Three steps treatment of keratoconus by ICRS implantation, CXL and phakic 
IOLS significantly improve UDVA, CDVA, higher order aberrations and corneal 
shape in moderate to severe keratoconus [57]. Moreover, keratometry (Ksteep, Kflat, 
Kmax) and refraction (sphere, SE, but not cylinder) were also improved [58]. The 
time interval between ICRS implantation and CXL was 4–6 weeks and ICL implan-
tation was performed 6–8 months after CXL [57, 58].
5.2.1.5 CXL in thin cornea
The 0.1% riboflavin in 20% dextran solution is used in original Dresden 
protocol. Only the anterior 300 μm of stroma can be treated [38, 59]. This 
standard technique requires corneal pachymetry more than 400 μm after de-
epithelization to decrease complications such as corneal stromal scar and corneal 
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endothelial cytotoxicity [47, 60]. In order to combat this issue, there are various 
modifications to the conventional CXL protocol for CXL in thin cornea. These 
modifications include hypoosmolar riboflavin, transepithelial CXL, iontopho-
resis-assisted CXL, Customized epithelial debridement technique, Lenticule-
assisted CXL, contact-lens- assisted CXL (CACXL) and individualized corneal 
CXL [60–67].
Hypoosmolar riboflavin has lower colloidal pressure (310 mOsmol/L vs. 402.7 
mOsmol/L in isotonic riboflavin) that causes stromal swelling to double its thick-
ness where stromal bed is less than 400 μm [60]. However, the efficacy of CXL 
using hypoosmolar riboflavin was lower than traditional CXL with isotonic ribofla-
vin. The possible theory to explain is that in hydrated corneas (using hypoosmolar 
riboflavin) concentration of collagen fibrils is decreased, hence fewer collagen 
fibrils are available for CXL [60, 61]. By changing the osmolarity of the riboflavin 
solution, while maintaining the concentration at 0.1%, probably does not alter 
the final riboflavin concentration in the cornea. On the contrary, modifying other 
parameters to obtain a more shallow depth of treatment; ie, the intensity of the 
UVA light, the duration of treatment, or the intensity of riboflavin concentra-
tion will alter the final riboflavin concentration in the cornea and require new 
dose–response assays [61]. Unfortunately, these modified techniques have not yet 
distinguished themselves as more effective than any other in terms of topographic 
or visual outcomes.
Despite the fact that CXL has a promising clinical outcomes, risk factors for 
ongoing ectasia include the application of isotonic riboflavin solution to thicken 
a thin cornea prior to treatment, corneas steeper than 58 D and age > 35 years 
[18, 68]. The most frequent definition of treatment failure is the continual pro-
gression of keratoconus with an enhancement of Kmax reading of 1.0 D 0r 1.5 D 
over the preoperative value [40, 47]. The outcomes of different CXL techniques 
are listed as in Table 4.
5.2.2 Intrastromal corneal ring segments (ICRS)
Intrastromal corneal ring segments (ICRS) were FDA-approved in 1999 for the 
treatment of low myopia. ICRS implantation causes displacement of the collagen 
fibers resulting in flattening of the central cornea and tissue adjacent to the ring is 
displaced forward [37]. ICRS are segments of polymethylmethacrylate (PMMA) 
plastic available in numerous arc-lengths, thicknesses, and designs. Five types of 
ICRS are available for keratoconus: 1) Intacs (Addition technology Inc.) 2) Intacs SK 
(Addition technology Inc.), 3) Ferrara Rings (Ferrara ophthalmics) and 4) Keraring 
(Mediphacos).5). MyoRing (Dioptex, GmbH, Linz, Austria). The devices are 
inserted into stromal tunnels that may be created manually using a corkscrew blade 
or femtosecond laser with no difference in results (except that channels tend to be 
slightly shallower when created manually and more often decentered when created 
by laser) [37]. The objective of ICRS implantation is to improve visual and topo-
graphic outcomes and restoration of contact lens tolerance [15, 18, 37]. Maximal 
flattening effect occurs with segments at 60–79% corneal thickness. Shallower than 
60%, the effect may be lessened and can induced ocular surface complications. 
On the contrary, deeper than 80%, there may have no topographic effect [88]. The 
outcome achieved is directly proportional to the thickness of the ICRS and inversely 
proportional to its diameter [37]. ICRS can be used alone or used in combination 
with other treatment options such as CXL for stabilizing disease progression [15]. 
The outcomes of ICRS are listed as in Table 4.
Although, ICRS has good visual and topographic results, some complications 





























Treatment Visual outcomes Refractive outcomes Topographic outcomes Disease progression
Standard CXL • VA either remains unchanged 
or improves by 1–2 lines  
[18, 38, 48, 49]
• Corneas steeper than 58 D, no 
benefit in UDVA or BCVA [68]
• Small reduction in 
astigmatism <0.5 D [18, 
70]
• variable, unpredictable 
corneal astigmatic cor-
rection [71]
• Sphere and cylinder was 
less negative, SE was 
more positive [49]
• Evening out of corneal parameters and a 
decline in overall surface variability [72]
• Flattening Kmean and Kmax by 1–2 D 
[18, 38, 48, 49]
• KFlat did not change [49]
• advanced KC may demonstrate changes 
more frequently than mild disease [18]
• Shortly after therapy, CCT may decline 
till 3 months but rebounds to baseline at 
1 year [39]
• Stop progression
> 90% -100% [68, 69, 74]










• 0.07 logMAR more improve-
ment in CDVA than standard 
CXL [69]
• Similar or lower UDVA with 
standard CXL [62, 69]
• No changes for the 
sphere, cylinder, and SE 
up to 12 months after 
CXL. [49]
• Lower SE than standard 
CXL [69]
• Similar increase refrac-
tive cylinder by 1.5 D and 
spherical refraction by 
1.0 D as standard CXL 
[69]
• Less effective than standard CXL to 
reduce Kmax (mean difference = 1.05D) 
[62]
• Kmax was reduced by 1.9–2.2 D,1 and 
3 months after CXL but not later [49]
• Stable Kmax (no flattening)or Kmax 
increase by 1.1 D [69, 73]
• Kmin was reduced by 0.6 to 0.8 D, 1 and 
3 months after CXL, and not later [49]
• Ksteep was reduced by 1.9 and 1.2 D, 6 
and 12 months, respectively, after CXL. 
[49]
• Kavg was not changed [49]
• Kflat, Ksteep increase slightly overtime 
(but decrease slightly overtime in 
standard CXL) [69]
• Similar change in CCT with standard 
CXL or stable CCT [62, 69]
• 23–55% progression of the 
disease between
1 year- 3 years after treatment 
[44, 69, 73]
• Stop progression 50% in pedi-

















Treatment Visual outcomes Refractive outcomes Topographic outcomes Disease progression
Accelerated CXL • No improvement in UDVA, 
BCVA [49]
• UDVA and BCVA increased 1 
Snellen line at 30 months [75]
• Compare to standard CXL at 
5 years [76]
• Similar improve in UDVA by 
0.o8 logMAR
• Similar improve in BCVA by 
0.06 logMAR
• Similar reduction in 
astigmatism by 0.8–0.9 
D, SE by 0.9 D when 
compare to standard 
CXL at 4 years [76]
• Cylinder increased by 0.7 
D 3 months after CXL, 
SE was more positive 
after 36 months by 1.07 
D, sphere data were not 
reported [49]
• Similar reduction in K with standard CXL 
(Kflat, Ksteep Kmean by 1 D and Kmax 
by 1.7–2.2 D, at 5 years) [49, 76]
• Greater reduction in Kmean than 
standard CXL [78]
• Epi-on was less effective than Epi-off 
Accelerated CXL to reduce Kmean, Kmax 
[75]
• Epi-on: stable CCT
• Epi-off: decreased during the first 
6 months and return to baseline at 1 year 
[75]
• Less or similar corneal thinning than 
standard CXL [78, 79]





• CDVA improved by 0.11 
logMAR at 6 months [49]
• BCVA improved by 0.2 logMAR 
at 1 year [77]
• BSCVA improved by 0.17 
logMAR at 2 years [46]
• Corneal astigmatism 
increased by 0.3 D at 
1 year [77]
• Kmax reduced by 1.2D at 1 year [77]
• Flattening of Kmean and Kmax by 0.58 
and 0.75 D at 2 years [46]
• Thinnest corneal pachymetry reduced by 
7–16 μm at 1–2 years [46, 77]
• CCT reduced by 6 μm at 2 years
All eyes show stability of Kmax, 


































• Improve 1–2 lines of BSCVA 
and BCVA
• Newer segment designs such 
as INTACS SK and Kerarings, 
visual gains still rarely exceed 
1–2 lines and may increase 
visual aberrations. [18]
• 10% lost ≥1 line of UDVA, and 
20% lost ≥1 line of BCVA [80]
• Sizable reduction in 
corneal astigmatism 
from 1 to 3 D
• Significant changes 
between 6 and 12 months
• Full refractive effect is 
not seen before 1 year 
postoperatively
• Appears stable, at least 
through 10 years of 
follow-up [18]
• Standard INTACS reduce mean Ks by 3–5 
D [18]
• INTACS SK, Kerarings, Ferrara ring, 
and Myoring reduce mean Ks by 2–9 
D (smaller internal diameters and are 
placed closer to the corneal center) [18]
Stop progression >90% for mild to 





• UDVA 20/50 to 20/100 [18]
• BCVA 20/30 to 20/40 [18]
• Average astigmatism 3 
to 5 D but may exceed 10 
D [18]
• 20% require refractive 
surgery after surgery [18]
• Suture removal tends to 
result in large unpre-
dictable swings in the 
amount of astigmatism
Donor button is
• oversized 0.5 mm; mean K around 45.5 D
• same-sized; mean K around 42.5 D [18]
Approximately 10% of eyes will 
display recurrent KC 20 years after 
PK; some diseased recipient cornea is 





• Descematic DALK; Similar/ 
better UDVA, BSCVA, BCVA to 
PK [18, 81]
• Pre-descematic DALK; inferior 
visual results to PK
• Fewer higher aberrations than 
PK [18]
• Same refractive out-
comes or more myopia 
than PK [18, 82]


















Treatment Visual outcomes Refractive outcomes Topographic outcomes Disease progression
Bowman layer 
transplantation
• BSCVA typically improves by 
1–2 lines
• BCVA usually remains 
unchanged [18]
• Slight hyperopic shift 
with no significant effect 
on corneal astigmatism 
[86, 87]
• Mean reduction in anterior simulated 
Ks 5 D
• max corneal power 5 to 7 D
• K max 8–9-D [86, 87]
• Non- significantly increase CCT, thinnest 
pachymetry [86]
• These topographic changes occur within 
the first post-operative month and appear 
stable through at least 2 years
• Stop progression
• 90% [87]
CXL = Corneal collagen cross-linking, PRK = Photorefractive keratectomy, IOL = intraocular lenses, UDVA = Uncorrected Distance visual acuity, CDVA = Corrected Distance visual acuity, BCVA = Best 
Corrected Visual Acuity, BSCVA = Best Spectacles Corrected visual acuity, D = Diopter, SE = spherical equivalent.
Other than standard CXL, formulation of riboflavin solutions, riboflavin concentration, total UVA energy that was used for each study may be different.
Table 4. 
Outcomes of surgical treatment of keratoconus.
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usually relate to corneal tunnel creation such as insufficient tunnel depth, asym-
metry or decentration, or Bowman’s layer perforation [15]. The post-operative 
complications have been reported such as corneal neovascularization, keratitis, 
deposits around ring segment, corneal haze, halos, pain, corneal melting or 
edema, segment extrusion, visual fluctuation, and photophobia [15]. This pro-
cedure is reversible and not preclude from further surgeries such as CXL and/or 
corneal transplantation. Due to complications such as stromal necrosis, segment 
extrusion of synthetic ICRS material, corneal allogenic ICRS (CAIRS) combined 
with CXL has been reported. Instead of using PMMA to create segment, CAIRS 
is trephined from donor cornea. CAIRS were implanted into mid-depth corneal 
tunnel that was created by femtosecond laser, followed by ACXL [89]. This proce-
dure has a promising result in term of improvement of UDVA by 2.79 lines, CDVA 
by 1.29 lines. Moreover, this procedure demonstrated improvement of SE, Kmax, 
Ksteep and topographic astigmatism and halt progression in all cases during follow 
period [89].
5.2.3 Corneal transplantation
Treatment options for advanced keratoconus that has corneal thickness less 
than 400 μm, Kmax more than 58 D may be limited to corneal transplantation that 
can stabilize the cone and enable continued contact lens wear [86]. The kerato-
plasty techniques may be penetrating keratoplasty (PK), Deep Anterior Lamellar 
Keratoplasty (DALK) or Bowman layer transplantation.
5.2.3.1 Penetrating keratoplasty (PK)
Penetrating or lamellar keratoplasty techniques are used depending on the 
extent of corneal scarring [15]. PK provides long term good vision but has slow 
visual rehabilitation from residual astigmatism and anisometropia [15]. Both PK 
and DALK tend to worsen any existing ocular surface problems, as both involve 
surface incisions, injury of corneal nerves, placement of long-lasting sutures, and 
requiring post-operative topical corticosteroids [18]. Despite the facts that long 
term graft survival following PK for keratoconus is good, averaging 97% at 5 years, 
90% at 10 years and 80% at 20–25 years, most of the patients with advanced KC are 
transplanted early in life, therefore it is more likely that more than one graft may be 
required over their lifetime ultimately [18].
5.2.3.2 Deep anterior lamellar keratoplasty (DALK)
The visual outcomes of BCVA, UDVA for DALK remains debated. The recent 
data from systematic review and meta-analysis demonstrated that the visual 
outcomes were worse [90] or better [81] than those for PK. The outcomes of 
DALK for keratoconus are better than PK [81] or equivalent [81] in terms of 
refractive error, astigmatism and rejection rate. Fifty percent of eyes may encoun-
ter Descemet membrane perforation which is the most significant intra-operative 
complications [18]. Other complications such as a double anterior chamber and 
persistent corneal edema have been reported. DALK may be less prone to second-
ary ocular hypertension because of their lower steroid requirement (owing to the 
smaller risk of rejection) [18]. Another advantage DALK is the lack of endothelial 
rejection because there is no endothelial defense reaction [15]. The reported rates 
of postoperative complications such as graft rejection, secondary glaucoma, 
complicated cataracts, and constant endothelial cell loss are lower with DALK 
than PK [15].
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5.2.3.3 Bowman layer transplantation
The PK or DALK may be disrupted by complications such as suture-related 
problems, graft rejection, epithelial wound-healing abnormalities, corneal cur-
vature changes due to progression of KC in the peripheral host cornea resulting 
in disappointing visual results [86]. In KC corneas, pathological changes include 
the reduction of number of keratocytes, organization of the stromal lamellae, 
fragmentation or absent of Bowman’s layer (BL) [91] It has been suggested that the 
BL may be the strongest biomechanical element of the human cornea followed by 
the anterior third of the cornea [92]. Therefore, the BL may play a structural role 
in maintaining the shape/tectonic stability in KC corneas [87]. This procedure was 
first described in 2014, Bowman’s layer graft was positioned inside the recipient 
corneal stroma in a sandwich technique, without corneal incision or sutures, to 
pull the anterior corneal surface flatter and create homogeneous corneal topog-
raphy [86]. BL transplantation can be performed under local anesthesia and low 
dose topical steroid can stop within 1 year post-operative, minimizing the risk of 
glaucoma development or cataract formation [86, 87, 93]. The reported complica-
tions are low such as intraoperative microperforation of the Descemet’s membrane 
[87, 93]. Because of the transplanted tissue is acellular, no episodes of allograft 
rejection have been observed [86, 87]. This procedure may postpone penetrating 
keratoplasty (PK) or deep anterior lamellar keratoplasty (DALK) and potentially 
allowed long term contact lens wear [86]. Although graft preparation and surgical 
technique can be challenging, assisted technologies, such as femtosecond laser 





Stage 1 Stage 2 Stage 3 Stage 4
Non- progressive Spectacles Spectacles
CL CL CL CL
CL intolerance CL intolerance
ICRS ICRS
BL transplantation BL transplantation
DALK/PK
Progressive Spectacles Spectacles
CL CL CL CL
CL intolerance CL intolerance
CXL CXL CXL
ICRS ICRS
BL transplantation BL transplantation
DALK/PK
Adapted from JAMA Ophthalmol. 2014 Apr 1;132(4):495–501.
The classification of keratoconus was based on Krumeich JH et al.A. Live-epikeratophakia for keratoconus. J 
Cataract Refract Surg. 1998 Apr;24(4):456–63. [17]
Stage 1 Kmax < 48 D, thickness > 500 μm, absence of scarring.
Stage 2 Kmax 48–53 D, thickness 400–500 μm, absence of scarring.
Stage 3 Kmax 54–55 D, thickness 200–400 μm, absence of scarring.
Stage 4 Kmax > 55 D, thickness < 200 μm, central corneal scarring.
Table 5. 
Management algorithm in various stages of keratoconus.
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help conquer these barriers [94, 95]. “Bowman layer onlay,” a recently developed 
surgical technique in which an isolated Bowman’s layer graft, is positioned onto the 
patient’s anatomical Bowman’s layer or anterior stroma, has demonstrated the rapid 
re-epithelization and integration of the tissue and comparable clinical outcomes to 
intrastromal transplantation [96]. The outcomes of each keratoplasty techniques 
are listed in Table 4.
There are a variety of nomograms for the treatment of keratoconus which are 
mainly focused on the keratoconus grading, risk factors, the progressive nature of 
the disease, and contact lens tolerance [15]. The management algorithm in various 
stages of keratoconus is shown in Table 5.
6. Future directions
Treatment for advanced KC has trended away from invasive procedures such as 
PK and even DALK toward minimally invasive procedures such as CXL, ICRS or BL 
transplantation. Although keratoconus is a multifactorial disease, the pathogenesis 
of the disease is very much affected by genetic factors and positive family his-
tory [2, 8, 97]. By identifying pathogenic genes and changing the structure of cell 
proteins, gene therapy may be a very promising and effective treatment modality to 
change the course of the disease [15].
7. Conclusion
The two most important goals of management of keratoconus are stopping dis-
ease progression and visual rehabilitation. An ocular allergy should be treated. Care 
providers should instruct the patients to avoid eye rubbing to halt disease progres-
sion. A careful follow up is needed to document disease progression and provide 
prompt treatment. A nonsurgical treatment of keratoconus includes spectacles or 
contact lens. Contact lens use does not slow or halt progression but can provide 
satisfactory vision in early stages of keratoconus. A contact lens type is selected 
based on the manifest refraction and the degree of keratoconus.
The five operations (CXL, ICRS, PK, DALK and BL transplantation) currently 
represent the available surgical treatment options for advanced KC. Treatment 
for advanced KC has trended away from invasive procedures such as PK and even 
DALK toward minimally invasive procedures such as CXL, ICRS or BL transplanta-
tion. CXL and ICRS were once regarded only for mild to moderate keratoconus, 
their roles are now expanding in advanced diseases as well.
PK and DALK provide long term good vision but has slow visual rehabilita-
tion and may be disrupted by complications such as suture-related problems and 
graft rejection. BL transplantation was introduced for advanced KC with extreme 
thinning/steepening. This novel procedure may postpone penetrating keratoplasty 
(PK) or deep anterior lamellar keratoplasty (DALK) and potentially allow long term 
contact lens wear. Since genetic factors play significant roles in KC, advances in gene 
therapy may soon yield innovative treatments of this disease.
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